TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02458443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric handgrip exercise using a hand dynamometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric handgrip exercise using a hand dynamometer
Study: NCT02065297

Intervention type: OTHER
Intervention: 1 blood sample

Intervention type: OTHER
Intervention: 1 blood sample
Study: NCT02458443

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric resistance training
Description: Isometric handgrip exercise using a hand dynamometer

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric resistance training
Description: Isometric handgrip exercise using a hand dynamometer
Study: NCT04439981

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ice cream
Description: Curcumin extract was added into ice cream

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ice cream
Description: Curcumin extract was added into ice cream
Study: NCT04126200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered.
Study: NCT02357108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
Study: NCT01835743

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
Study: NCT02174835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study: NCT02357108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
Study: NCT02065297

Intervention type: OTHER
Intervention: 1 blood sample

Intervention type: OTHER
Intervention: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
Study: NCT02357108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
Study: NCT02174835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVP-923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVP-923
Study: NCT02932904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine Overencapsulated Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine Overencapsulated Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine Overencapsulated Tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine Placebo-matching Capsules.
Study: NCT02701972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACE Device
Description: Implanted BACE device
Study: NCT02357108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
Study: NCT03727906

Intervention type: OTHER
Group type: OTHER
Intervention: No pre-sleep arousal manipulation
Description: As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.

Intervention type: OTHER
Group type: OTHER
Intervention: No pre-sleep arousal manipulation
Description: As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.

Intervention type: OTHER
Group type: OTHER
Intervention: pre-sleep arousal down-regulation
Description: On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process.

Intervention type: OTHER
Group type: OTHER
Intervention: pre-sleep arousal down-regulation
Description: On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process.

Intervention type: OTHER
Group type: OTHER
Intervention: pre-sleep arousal up-regulation
Description: On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone).

Intervention type: OTHER
Group type: OTHER
Intervention: pre-sleep arousal up-regulation
Description: On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone).
Study: NCT01640899

Intervention type: DEVICE
Group type: OTHER
Intervention: Shoe Insoles
Description: Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
Study: NCT00284310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anamnesis and clinical examination
Description: Anamnesis and clinical examination to follow.
Study: NCT04036500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Tablets
Description: Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
Study: NCT00428389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 5 cm^2 transdermal patch
Description: Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 5 cm^2 transdermal patch
Description: Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 10 cm^2 transdermal patch
Description: Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 10 cm^2 transdermal patch
Description: Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
Study: NCT04087135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct laryngoscopy
Description: Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videolaryngoscopy McGrath
Description: Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videolaryngoscopy McGrath with suction
Description: Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
Study: NCT00951652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal and emotional processing therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supportive listening
Study: NCT02401451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhythmPadGP
Description: ECG acquisition using a novel device RhythmPadGP
Study: NCT01876693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic percutaneous gastrostomy
Description: prophylactic percutaneous gastrostomy with nutrition counselling
Study: NCT00734253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxamine Dihydrochloride
Description: 150 mg capsules taken orally twice a day for 1-year.
Study: NCT01366885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
Study: NCT02464514

Intervention type: OTHER
Group type: OTHER
Intervention: High carbohydrate meal
Description: 65% carbohydrate, 17% protein, and 18% fat

Intervention type: OTHER
Group type: OTHER
Intervention: High carbohydrate meal
Description: 65% carbohydrate, 17% protein, and 18% fat

Intervention type: OTHER
Group type: OTHER
Intervention: High fat meal
Description: 58% fat, 17% protein, and 25% carbohydrate

Intervention type: OTHER
Group type: OTHER
Intervention: High fat meal
Description: 58% fat, 17% protein, and 25% carbohydrate
Study: NCT03018977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The sedative weaning protocol group
Description: After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The usual group
Description: After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
Study: NCT02782221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegisomant
Description: One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
Study: NCT00996255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-793887
Description: Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
Study: NCT02878837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT05502510

Intervention type: BEHAVIORAL
Intervention: MyHealthyPregnancy
Description: MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
Study: NCT03515564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance/Movement Therapy, Art Therapy, Mindful Yoga
Description: Utilizing deep breathing, exercise modalities, and social support in all settings
Study: NCT04956653

Intervention type: OTHER
Intervention: Without additional intervention
Description: Only patients' information was collected

Intervention type: OTHER
Intervention: Without additional intervention
Description: Only patients' information was collected

Intervention type: OTHER
Intervention: Without additional intervention
Description: Only patients' information was collected
Study: NCT04405076

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection
Study: NCT00734253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxamine Dihydrochloride
Description: 300 mg capsules taken twice a day for 1-year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken twice a day for 1-year
Study: NCT02424305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel 0.018%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel 0.1%
Study: NCT04405076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection
Study: NCT02424305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel 0.037%
Study: NCT03272815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Device (PD)
Description: A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
Study: NCT04405076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT01881659

Intervention type: OTHER
Intervention: HPV screening
Description: Women who signed informed consent will be screened with HPV testing.
Study: NCT03272815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound (US)
Description: The SonoSite hand help portable ultrasound device.
Study: NCT04405076

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Sterile liquid for injection
Study: NCT04330560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise telemonitoring connects to healthcare platform
Description: The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise self-monitoring
Description: The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise teleconsultation
Description: Conducted through smartphone video call app.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise teleconsultation
Description: Conducted through smartphone video call app.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Other CR components
Description: Including dietary, psychology, education conducted at the center.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Other CR components
Description: Including dietary, psychology, education conducted at the center.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Undergoing standard care by cardiac rehabilitation at the center
Study: NCT02140658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multiple health education interventions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: conventional health education
Study: NCT00702117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flecainide
Description: 2 mg/kg iv in 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flecainide
Description: 2 mg/kg iv in 10 minutes
Study: NCT02357108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
Study: NCT01640288

Intervention type: DRUG
Group type: OTHER
Intervention: Perfluorinated Gas/Oxygen Mixture
Description: 19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
Study: NCT00702117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ajmaline
Description: 1 mg/kg iv in 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ajmaline
Description: 1 mg/kg iv in 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ajmaline
Description: 1 mg/kg iv in 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: procainamide
Description: 10 mg/kg iv in 10 minutes
Study: NCT04318496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Press Tack Acupuncture
Description: PYONEX Φ0.20×0.6 mm made by Seirin Corporation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Press Tack Placebo
Description: PYONEX placebo sticker made by Seirin Corporation
Study: NCT02578654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategies to improve HIV care engagement
Description: Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period.
Study: NCT00319826

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention
Study: NCT03891654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast Enhanced Computed Tomography
Description: Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
Study: NCT01120613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronotherapy
Description: Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~1. ACE or ARB~2. Calcium Channel Blockers~3. Alpha Blocker~4. Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed.
Study: NCT04327999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Description: Self-Administered - utilizing eye drop preservative free vials
Study: NCT04079478

Intervention type: OTHER
Intervention: AI
Description: Artificial intellignece colonoscopy
Study: NCT03394768

Intervention type: OTHER
Intervention: No additional intervention
Description: Patients will be treated as per department protocols and no additional intervention will be performed

Intervention type: OTHER
Intervention: No additional intervention
Description: Patients will be treated as per department protocols and no additional intervention will be performed
Study: NCT00944151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Catheter and Infusion of Study Solution
Description: Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Catheter and Infusion of Study Solution
Description: Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
Study: NCT03588221

Intervention type: PROCEDURE
Group type: OTHER
Intervention: four sets of hand hygiene measurements per participant
Description: 1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds

Intervention type: PROCEDURE
Group type: OTHER
Intervention: four sets of hand hygiene measurements per participant
Description: 1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds